Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies

This study was aimed to enhance the dissolution rate, oral bioavailability and analgesic potential of the aceclofenac (AC) in the form of nanosuspension using cost-effective simple precipitation–ultrasonication approach. The nanocrystals were produced using the optimum conditions investigated for AC...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Drug Design, Development and Therapy
المؤلف الرئيسي: 2-s2.0-85028647685
التنسيق: مقال
اللغة:English
منشور في: Dove Medical Press Ltd. 2017
الوصول للمادة أونلاين:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028647685&doi=10.2147%2fDDDT.S140626&partnerID=40&md5=a63bf74942ce3b46edf3dd86044aec31
id Rahim H.; Sadiq A.; Khan S.; Khan M.A.; Shah S.M.H.; Hussain Z.; Ullah R.; Shahat A.A.; Ibrahim K.
spelling Rahim H.; Sadiq A.; Khan S.; Khan M.A.; Shah S.M.H.; Hussain Z.; Ullah R.; Shahat A.A.; Ibrahim K.
2-s2.0-85028647685
Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
2017
Drug Design, Development and Therapy
11

10.2147/DDDT.S140626
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028647685&doi=10.2147%2fDDDT.S140626&partnerID=40&md5=a63bf74942ce3b46edf3dd86044aec31
This study was aimed to enhance the dissolution rate, oral bioavailability and analgesic potential of the aceclofenac (AC) in the form of nanosuspension using cost-effective simple precipitation–ultrasonication approach. The nanocrystals were produced using the optimum conditions investigated for AC. The minimum particle size (PS) and polydispersity index was found to be 112±2.01 nm and 0.165, respectively, using hydroxypropyl methylcellulose (1%, w/w), polyvinylpyrrolidone K30 (1%, w/w) and sodium lauryl sulfate (0.12%, w/w). The characterization of AC was performed using zeta sizer, scanning electron microscopy, transmission electron microscopy, powder X-ray diffraction and differential scanning calorimetry. The saturation solubility of the AC nanocrystals was substantially increased 2.6- and 4.5-fold compared to its unprocessed active pharmaceutical ingredient in stabilizer solution and unprocessed drug. Similarly, the dissolution rate of the AC nanocrystals was substantially enhanced compared to its other counterpart. The results showed that .88% of AC nanocrystals were dissolved in first 10 min compared to unprocessed AC (8.38%), microsuspension (66.65%) and its marketed tablets (17.65%). The in vivo studies of the produced stabilized nanosuspension demonstrated that the Cmaxwere 4.98- and 2.80-fold while area under curve from time of administration to 24 h (AUC0→24 h) were found 3.88- and 2.10-fold greater when compared with unprocessed drug and its marketed formulation, respectively. The improved antinociceptive activity of AC nanocrystals was shown at much lower doses as compared to unprocessed drug, which is purely because of nanonization which may be attributed to improved solubility and dissolution rate of AC, ultimately resulting in its faster rate of absorption. © 2017 Rahim et al.
Dove Medical Press Ltd.
11778881
English
Article
All Open Access; Gold Open Access; Green Open Access
author 2-s2.0-85028647685
spellingShingle 2-s2.0-85028647685
Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
author_facet 2-s2.0-85028647685
author_sort 2-s2.0-85028647685
title Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
title_short Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
title_full Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
title_fullStr Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
title_full_unstemmed Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
title_sort Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: Formulation optimization, characterization, analgesic and acute toxicity studies
publishDate 2017
container_title Drug Design, Development and Therapy
container_volume 11
container_issue
doi_str_mv 10.2147/DDDT.S140626
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028647685&doi=10.2147%2fDDDT.S140626&partnerID=40&md5=a63bf74942ce3b46edf3dd86044aec31
description This study was aimed to enhance the dissolution rate, oral bioavailability and analgesic potential of the aceclofenac (AC) in the form of nanosuspension using cost-effective simple precipitation–ultrasonication approach. The nanocrystals were produced using the optimum conditions investigated for AC. The minimum particle size (PS) and polydispersity index was found to be 112±2.01 nm and 0.165, respectively, using hydroxypropyl methylcellulose (1%, w/w), polyvinylpyrrolidone K30 (1%, w/w) and sodium lauryl sulfate (0.12%, w/w). The characterization of AC was performed using zeta sizer, scanning electron microscopy, transmission electron microscopy, powder X-ray diffraction and differential scanning calorimetry. The saturation solubility of the AC nanocrystals was substantially increased 2.6- and 4.5-fold compared to its unprocessed active pharmaceutical ingredient in stabilizer solution and unprocessed drug. Similarly, the dissolution rate of the AC nanocrystals was substantially enhanced compared to its other counterpart. The results showed that .88% of AC nanocrystals were dissolved in first 10 min compared to unprocessed AC (8.38%), microsuspension (66.65%) and its marketed tablets (17.65%). The in vivo studies of the produced stabilized nanosuspension demonstrated that the Cmaxwere 4.98- and 2.80-fold while area under curve from time of administration to 24 h (AUC0→24 h) were found 3.88- and 2.10-fold greater when compared with unprocessed drug and its marketed formulation, respectively. The improved antinociceptive activity of AC nanocrystals was shown at much lower doses as compared to unprocessed drug, which is purely because of nanonization which may be attributed to improved solubility and dissolution rate of AC, ultimately resulting in its faster rate of absorption. © 2017 Rahim et al.
publisher Dove Medical Press Ltd.
issn 11778881
language English
format Article
accesstype All Open Access; Gold Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1828987879659929600